Abstract
The development of alternative medications for urate-lowering therapies is imperative for patients that are intolerant to current treatments. Despite GWAS have identified hundreds of loci associated with serum urate levels, the mechanistic understanding and discovery of drug targets remain difficult. This difficulty arises from the multiple-independent-associations challenge in the genomic studies of complex diseases as hyperuricemia. Here, we introduced a locus-specific stratification (LSS) and gene regulatory prioritization score (GRPS) approach to address the multiple-independent-associations challenge. By integrating with kidney single-cell chromatin accessibility and gene expression, LSS identified functional SNPs, regulatory elements, and genes for 118 loci. The interpretability was increased by 1.4 to 5.2 fold. GRPS prioritized genes and nominated under-explored drug target with high confidence, which was validated using CRISPR activation and phenotypic assays. Our findings not only identified top causal genes but also proposed the regulatory mechanisms for pathogenic genes, expanding our knowledge of the genetic contribution in complex diseases as hyperuricemia.
One-sentence summary A novel approach to comprehensively explore genetic contribution and nominate reliable causal genes for complex diseases as hyperuricemia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
J.Y. is grateful to support from The Open Project of Jiangsu Provincial Science and Technology Resources (Clinical Resources) Coordination Service Platform JSRB2021-01. S. S. is grateful to support from National Natural Science Foundation of China (82170723).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The kidney scATAC-seq publicly available data used in this study are available in the Gene Expression Omnibus (GEO) under GSE166547. The kidney scRNA-seq data used in this study are publicly available in the GEO under GSE131882. Kidney tubule eQTL derives from NephQTL browser (https://www.nephqtl.org). Epigenomic profiles from EpiMap is available at http://compbio.mit.edu/epimap/. GWAS datasets used in this study are downloaded from CKDGen Consortium (https://ckdgen.imbi.uni-freiburg.de).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The kidney scATAC-seq publicly available data used in this study are available in the Gene Expression Omnibus (GEO) under GSE166547. The kidney scRNA-seq data used in this study are publicly available in the GEO under GSE131882. Kidney tubule eQTL derives from NephQTL browser (https://www.nephqtl.org). Epigenomic profiles from EpiMap is available at http://compbio.mit.edu/epimap/. GWAS datasets used in this study are downloaded from CKDGen Consortium (https://ckdgen.imbi.uni-freiburg.de).
